Prana Biotechnology Current Ratio 2006-2020 | ATHE
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Prana Biotechnology current ratio from 2006 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Prana Biotechnology Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2020-12-31 |
$0.03B |
$0.00B |
12.28 |
| 2020-06-30 |
$0.01B |
$0.00B |
3.62 |
| 2019-12-31 |
$0.01B |
$0.00B |
4.43 |
| 2019-06-30 |
$0.01B |
$0.00B |
5.98 |
| 2018-12-31 |
$0.01B |
$0.00B |
4.37 |
| 2018-06-30 |
$0.01B |
$0.00B |
7.09 |
| 2017-12-31 |
$0.02B |
$0.00B |
12.12 |
| 2017-06-30 |
$0.02B |
$0.00B |
15.99 |
| 2016-12-31 |
$0.02B |
$0.00B |
10.66 |
| 2016-06-30 |
$0.03B |
$0.00B |
14.34 |
| 2015-12-31 |
$0.03B |
$0.00B |
16.41 |
| 2015-06-30 |
$0.04B |
$0.00B |
15.39 |
| 2014-12-31 |
$0.03B |
$0.00B |
12.09 |
| 2014-06-30 |
$0.04B |
$0.00B |
10.54 |
| 2013-12-31 |
$0.02B |
$0.00B |
5.16 |
| 2013-06-30 |
$0.02B |
$0.00B |
5.48 |
| 2012-12-31 |
$0.01B |
$0.00B |
3.81 |
| 2012-06-30 |
$0.01B |
$0.00B |
4.23 |
| 2011-12-31 |
$0.01B |
$0.00B |
3.64 |
| 2011-06-30 |
$0.01B |
$0.00B |
4.31 |
| 2010-12-31 |
$0.00B |
$0.00B |
3.25 |
| 2010-06-30 |
$0.01B |
$0.00B |
4.48 |
| 2009-12-31 |
$0.01B |
$0.00B |
9.53 |
| 2009-06-30 |
$0.00B |
$0.00B |
5.68 |
| 2008-12-31 |
$0.01B |
$0.00B |
4.04 |
| 2008-06-30 |
$0.01B |
$0.00B |
6.65 |
| 2007-12-31 |
$0.01B |
$0.00B |
4.94 |
| 2007-06-30 |
$0.01B |
$0.00B |
4.43 |
| 2006-12-31 |
$0.01B |
$0.00B |
10.29 |
| 2006-06-30 |
$0.01B |
$0.00B |
6.43 |
| 2005-12-31 |
$0.01B |
$0.00B |
14.41 |
| 2005-06-30 |
$0.02B |
$0.00B |
8.38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.029B |
$0.003B |
|
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
|
